Fig 1. Overall survival and responses to autoantibody reduction therapy.
A) Cumulative survival of the 24 IPF patients with acute exacerbations. Most of the mortality occurred during the first month after their presentation. Number in parentheses denotes subjects censored at the end of the observation period. B) Supplemental oxygen requirements necessary to maintain resting SaO2 >92% were reduced in 15 AE-IPF patients. Three others (requiring only room air while at rest) increased their six minute walk distances by >30 meter during therapy, and are not shown here. C) Survival was prolonged among the 18 AE-IPF who responded to autoantibody reduction therapy with lessened oxygen requirements and/or increased walk distances, in comparison to those patients who had no evident beneficial response to the treatments. HR = hazard ratio; 95%CI = 95% confidence interval. Number in parentheses denotes subjects censored at the end of the observation period.